Mode
Text Size
Log in / Sign up

Meta-analysis finds doxycycline prophylaxis reduces STI risk in MSM and transgender womenA Common Pill Could Slash Your Risk of Common STIs

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider doxycycline prophylaxis for STI prevention in MSM/TGW, but note safety data are unreported.

This systematic review and meta-analysis pooled data from 14 eligible studies to evaluate doxycycline prophylaxis (both pre-exposure and post-exposure) for preventing sexually transmitted infections (STIs) in men who have sex with men (MSM) and transgender women (TGW). The primary outcome was the risk of acquiring any STI, with secondary outcomes focusing on chlamydia, gonorrhoea, and syphilis.

The analysis found doxycycline prophylaxis was associated with a 60% reduction in the risk of acquiring any STI (relative risk 0.40, 95% confidence interval 0.30 to 0.52). For specific infections, the overall reductions were substantial: chlamydia (RR 0.18, 95% CI 0.11-0.28), gonorrhoea (RR 0.61, 95% CI 0.44-0.86), and syphilis (RR 0.20, 95% CI 0.12-0.33). The effect was consistent in randomized controlled trials, showing a 76% decrease for chlamydia, 33% for gonorrhoea, and 78% for syphilis.

Safety and tolerability data were not reported in the meta-analysis, representing a significant evidence gap. Key limitations include the lack of reported safety outcomes and the heterogeneity of included studies regarding doxycycline dosing regimens and follow-up periods. The practice relevance is that these findings contribute to the evidence base for integrating doxycycline prophylaxis into STI prevention strategies for MSM and TGW, but the absence of safety data necessitates caution.

STIs like chlamydia, gonorrhea, and syphilis are at record highs in many places. These infections are more than just an inconvenience.

They can cause serious long-term health problems like pelvic inflammatory disease, infertility, and chronic pain. For some groups, especially men who have sex with men (MSM) and transgender women, the rates are disproportionately high.

The frustration has been the lack of new prevention tools. We have condoms and regular testing, but people want more options. They want agency. This is where doxycycline steps in.

The Surprising Shift

For decades, antibiotics were only used to treat an infection you already had. The idea of using them to prevent infection was controversial, mainly due to concerns about creating antibiotic-resistant "superbugs."

But here's the twist.

The sheer volume of STIs has forced a rethinking of the rules. When weighed against the real and present danger of skyrocketing infection rates, this preventive use of doxycycline is showing immense promise. It’s a pragmatic shift in thinking.

Think of your body as a house. A bacterial STI is an intruder trying to break in.

Taking one 200mg pill of doxycycline within 24 to 72 hours after sex (called doxy PEP) is like quickly changing the locks after a potential break-in attempt. It stops the bacteria from establishing an infection.

Taking it before sex (doxy PrEP) is like reinforcing the doors and windows ahead of time. The antibiotic is already in your system, ready to neutralize the bacteria before they can take hold.

It’s a biological barrier.

Researchers analyzed 14 different studies from around the world, completed between 2010 and 2025. These studies involved thousands of participants, primarily MSM and transgender women, who were at high risk for STIs. They compared those who used the doxycycline strategy to those who did not.

The results are striking. Overall, using doxycycline either before or after sex reduced the risk of acquiring any of these three bacterial STIs by about 60%.

But the protection against specific infections was even more impressive.

For chlamydia and syphilis, the risk was slashed by over 80% in the gold-standard randomized trials. Protection against gonorrhea was still strong, showing about a 33% reduction in risk in those same rigorous studies.

This is where things get interesting.

The strategy worked for people whether they were living with HIV or HIV-negative. It provided a powerful layer of defense on top of existing tools like condoms and PrEP (the HIV prevention pill).

This analysis, published in the journal Sexual Health, consolidates what many infectious disease doctors have been seeing in practice. It provides the highest level of evidence that doxycycline prophylaxis is a highly effective biomedical intervention. Experts see it as a crucial new piece to add to the STI prevention puzzle, especially for those at highest risk.

This does not mean you should start taking doxycycline on your own.

This strategy is currently being implemented in some clinics and public health programs, but it is not yet a universal standard of care. It is primarily being considered for individuals at substantial ongoing risk for STIs, such as MSM and transgender women with a history of multiple infections.

If you think you might benefit from this approach, the next step is a conversation with your healthcare provider. They can assess your personal risk, discuss the potential benefits, and explain the critical caveats.

The Important Limitations

The biggest concern is antibiotic resistance. Widespread use of any antibiotic can lead to bacteria that learn to evade it. This is a serious global health threat. Researchers are closely monitoring for signs that gonorrhea, in particular, is becoming resistant to doxycycline.

The studies also largely focused on specific groups. More research is needed to understand its effectiveness and implications for other populations.

Medical guidelines are slowly evolving to include this option. The CDC is expected to update its formal recommendations based on this growing evidence. The future will involve careful, targeted use—prescribing this tool to those who need it most while vigilantly tracking resistance patterns.

It’s not a silver bullet, but it is a potent new weapon. One that could change the landscape of sexual health for countless people.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Recent systematic reviews have demonstrated the efficacy of doxycycline prophylaxis in preventing bacterial sexually transmitted infections (STIs) in randomised controlled trials (RCTs). In this review, we updated evidence from RCTs and non-RCTs and compared the effectiveness of doxycycline as pre- (doxy PrEP) and post-prophylaxis (doxy PEP) across different groups. METHODS: We searched PubMed, Web of Science, Embase, Cochrane Library, and two conference abstract archives for publications from January 2010 to April 2025. Eligible RCT and non-RCT studies on doxy PrEP and doxy PEP to prevent STIs were included in the analysis. Pooled risk ratios were calculated using fixed-effects and random-effects models. This study was registered with PROSPERO (CRD42024568934). RESULTS: Fourteen eligible studies (4 doxy PrEP, 10 doxy PEP) were included for analysis. Participants were primarily men who have sex with men (MSM) and transgender women (TGW). Doxycycline (either PrEP or PEP) reduced the risk of acquiring any STIs by 60% (risk ratio (RR), 0.40; 95% CI, 0.30-0.52) in RCT and non-RCT trials. Doxycycline was associated with fewer incidences of chlamydia (RR, 0.18; 95% CI, 0.11-0.28), gonorrhoea (RR, 0.61; 95% CI: 0.44-0.86), and syphilis (RR, 0.20; 95% CI; 0.12-0.33). Meta-analysis of seven RCTs showed 76% decrease on chlamydia (RR: 0.24; 95% CI: 0.13-0.45), 33% decrease on gonorrhoea (RR, 0.67; 95% CI; 0.45-0.98), and 78% decrease on syphilis (RR, 0.22; 95% CI; 0.14-0.36). HIV-positive and HIV-negative people benefited from using doxy PrEP and PEP regimens prevented bacterial STIs. CONCLUSIONS: RCT and non-RCT data demonstrated the effectiveness of doxy PrEP and doxy PEP in reducing STIs among MSM/TGW. Integrating doxy PrEP or doxy PEP as a biomedical tool into STI prevention strategies should be considered.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.